Gemfibrozil and Repaglinide interaction

Gemfibrozil and Repaglinide: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Gemfibrozil (Lopid) label · effective 2026-05-21

Major

Combination therapy of gemfibrozil with repaglinide (see PRECAUTIONS ).

Contraindicationsnames RepaglinideView label on DailyMed
Major

Combination therapy of gemfibrozil with simvastatin or with repaglinide, which are OATP1B1 substrates, is contraindicated (see CONTRAINDICATIONS ).

Warningsnames RepaglinideView label on DailyMed
Major

Co-administration of gemfibrozil and repaglinide increases the risk of severe hypoglycemia and is contraindicated (see CONTRAINDICATIONS ).

Drug interactionsnames RepaglinideView label on DailyMed
Moderate

Repaglinide In healthy volunteers, co-administration with gemfibrozil (600 mg twice daily for 3 days) resulted in an 8.1-fold (range 5.5- to 15.0- fold) higher repaglinide AUC and a 28.6-fold (range 18.5- to 80.1-fold) higher repaglinide plasma concentration 7 hours after the dose.

Drug interactionsnames RepaglinideView label on DailyMed
Moderate

In the same study, gemfibrozil (600 mg twice daily for 3 days) + itraconazole (200 mg in the morning and 100 mg in the evening at Day 1, then 100 mg twice daily at Day 2–3) resulted in a 19.4- (range 12.9- to 24.7-fold) higher repaglinide AUC and a 70.4-fold (range 42.9- to 119.2-fold) higher repaglinide plasma concentration 7 hours after the dose.

Drug interactionsnames RepaglinideView label on DailyMed

From the Repaglinide label · effective 2025-05-02

Major

Repaglinide tablets are contraindicated in patients with: Concomitant use of gemfibrozil [see Drug Interactions (7.1) ] .

Contraindicationsnames GemfibrozilView label on DailyMed
Major

Concomitant use with gemfibrozil ( 4 )

Contraindicationsnames GemfibrozilView label on DailyMed
Major

Intervention: Do not administer repaglinide tablets to patients receiving gemfibrozil [see Contraindications (4) ] .

Drug interactionsnames GemfibrozilView label on DailyMed
Moderate

Table 3: Clinically Important Drug Interactions with Repaglinide Tablets Gemfibrozil Clinical Impact: Gemfibrozil significantly increased repaglinide tablets exposures by 8.1 fold [see Clinical Pharmacology (12.3) ].

Drug interactionsnames GemfibrozilView label on DailyMed
Minor

Drugs that are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast, deferasirox, and clopidiogrel.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.